Netarsudil mesylate

Drug Profile

Netarsudil mesylate

Alternative Names: AR-13224; AR13324; Netarsudil ophthalmic solution - Aerie Pharmaceuticals; Rhopressa

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Rho-associated kinase inhibitors; Transforming growth factor beta type II receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Glaucoma; Ocular hypertension
  • Preclinical Neurological disorders

Most Recent Events

  • 28 Feb 2017 Aerie Pharmaceuticals resubmits NDA to the US FDA for netarsudil mesylate for Glaucoma and Ocular hypertension
  • 28 Feb 2017 Preregistration for Glaucoma in USA (Ophthalmic)
  • 28 Feb 2017 Preregistration for Ocular hypertension in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top